Articles

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard School of Public Health, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
Vol. 101 No. 10 (2016): October, 2016 https://doi.org/10.3324/haematol.2015.141176